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Glial cell line-derived neurotrophic factor (GDNF) family ligands 
(GFLs) and their receptor (GFRα) complex functions are well-known in 
neurobiology. There are emerging evidences showing their involvement in 
tumour biology.  GDNF is known to induce neuronal stem cell and neuronal 
progenitor cell survival and differentiation. The effects of another GFL, 
neurturin (NTN), and the specific roles of GDNF receptor (GFR) isoforms are 
currently poorly understood in neuronal differentiation and tumor biology.  In 
this study, using the Ntera2 neuronal model, the regulation of the expressions 
of the GFR system was examined; and the profile of neuronal lineages during 
differentiation induced by different GFLs was investigated.  GLF stimulation 
after stimulating with RA did not affect neuronal differentiation.  However, 
the profiles of neuronal lineage markers appeared to change upon such 
stimulation.  Furthermore, GFRα expression remained largely unchanged 
when cultured in 2D or 3D culture with the exception of NCAM expression, 
which suggested that GFRα might play a role in neuronal differentiation in 
different culturing condition.  The roles of specific GFRα1 isoforms and their 
co-receptor (Ret), in human breast tumor biology, were investigated using 
siRNA based gene knockdown studies.  It was found that Ret appeared to be 
the most significant component of the GDNF signaling pathway in the 
maintenance of MCF7 survival and/or proliferation, while GFRα1 appeared to 
have no isoform specific role in the maintenance of MCF7 cells with GDNF 
stimulation.  Overall, these studies have provided insights into the roles of 
GFR systems in neuronal differentiation and their roles in breast cancer 
progression.     
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1.1 GDNF family of ligands (GFLs)  
 Glial cell line-derived neurotrophic factor (GDNF) is the prototype 
belonging to a family of structurally related molecules distantly related to the 
TGF-β superfamily with conserved cystine knots.  Currently, four members of 
GFLs, named GDNF, Neurturin (NTN), Artemin (ART, also named as Enovin 
or neublastin), and Persephin (PSP), have been identified in mammals.  GDNF 
was originally isolated and purified from the conditioned media derived from 
B49, a rat glioma cell-line, was known to secrete potent trophic factors that 
support the survival of midbrain dopamine neurons in vitro[1].  Similarly, 
NTN was isolated and purified from the conditioned media derived from 
Chinese hamster ovary cells; which was shown to support the long-term 
survival of cultured superior cervical ganglion sympathetic cells [2].  On the 
other hand, PSP was later identified using homology-based PCR screening [3], 
while ART, yet another GFL in the family, was identified by database 
searches [4].  Additional searches, including a recent detailed search 
conducted on  the  human  genome  database (NCBI build 36.3) in an attempt 
to identify further GFLs did not appear to yield any other GFLs.  Since the 
discoveries, orthologs of all four GFLs have been reported in almost all 
vertebrates which includes bony fishes; but NTN is reportedly absent in 





Figure 1.1 Structures of GDNF family of ligands (GFLs).  (A) Schematic 
representation of a homodimeric GFL with intra- and intermolecular bridges 
formed between cysteine residues designated by “C”.  (B) Sequence alignment 
of human GFLs.  The secondary-structural elements within the GFL structures 
are shown above the sequences by designation for alpha helices (coil) and beta 
strands (arrows).  (C) RasMol representation of the GDNF monomer based on 
coordinates described [PDB ID 1AGQ; 51].  This figure is adapted from 
Figure 1, Wan et al, Neurogenesis, Neurodegeneration and 
Neuroregeneration 201-243 ISBN: 978-81-308-0388-3.   
 
 
 All GFLs are encoded by single copy genes and their expressions have 
been identified in various regions of the nervous system, which further 
supports the notion that GFLs are neurotrophic factors highly involved in the 
development, functional activity and maintenance of neuronal systems [6-9].  
GFLs are also found to possess multiple variants, as multiple transcripts of 
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GDNF [10-16], ART [17] and PSP [18] have been reportedly found in 
different tissues, likely due to alternative splicing and processing in the 
specific tissues.  The expressions of these tissue specific transcripts are 
specifically regulated by external factors, such as lipopolysaccharide or the 
extensive loss of dopaminergic (DA) neurons and striatal dopamine [16, 19].  
The GFL transcripts are biosynthesized and secreted as glycoproteins by 
various tissues, including neurons [6, 20, 21].  All GFLs glycoproteins are 
produced as precursors, preproGFLs.  They are further processed by 
proteolytic cleavages, and further glycosylated and disulphide linked to 
produce mature GFLs.  Among them, the mature form of GDNF is 
anterogradely transported in axons and dendrites to synapses and plays a role 
in neuronal plasticity [22-26].  
 Structurally, GFLs belong to the cysteine-knot proteins family which 
shared similar topologies and function as homodimers[27].  GFLs do not share 
high amino acid sequence homologies between each other, but all possess 
seven conserved cysteine (Cys) residues (Figure 1.1).  The GDNF crystalline 
structure contains an asymmetric unit of two antiparallel covalent homodimers.  
These dimers have different hinge angle between the “wrist” and “finger loops” 
within their respective monomers [28].  While there are high similarities in the 
overall topology of the GFLs, detailed analyses on covalent homodimer of 
ART when compared to GDNF showed a degree of differences in shape and 
possible flexibility of the elongated homodimer[29]. Studies have indicated 
that the two finger loops of GFLs directly interact with their respective co-
receptors; and when GFLs are complexed to their cognate receptors, they 
resemble the structure of the GFL monomer [29-32].   
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1.2 GDNF family of receptors (GFRs), co-receptors Ret and NCAM 
 The homodimeric GFLs have been shown to activate downstream 
signaling via the formation of a canonical multi-component receptor complex 
comprising a preferred high-affinity GDNF family receptor alpha (GFRα) and 
its co-receptor, Ret (REarranged during Transformation) with a proposed 
stoichiometry of  GFL homodimer-(GFRα)2-(Ret)2. 
 GFRα1 is synonymous with GFRA1, GDNFR, GDNFR-ALPHA, 
GDNFRA, GFR-ALPHA-1, TRNR1, MGC23045, RET1L, RETL1 and 
GDNFRA1.  Similarly, GFRα2 is synonymous with GFRA2, GDNFR-BETA, 
GDNFRB, GFR-ALPHA-2, RETL2, NRTNR-ALPHA, NTNR-ALPHA, 
NTNRA and TRNR2.  Therefore, in order to unify the various synonyms to 
prevent mis-information, a nomenclature was proposed to define the multi-
components of this receptor complex [33].  Hence, the component that directly 
binds the GFLs is concordantly known as the "α" subunit while the accessory 
component, Ret, is coined the "β" subunit.  The former "α" term is now widely 
used, but conversely the latter "β" term is seldom used to define the accessory 
subunits. 
 In mammals, there are four GFRα paralogues, named GFRα1 to 4, and 
each of them is encoded by their respective single gene found on different 
chromosomal locus.  GFRα receptors are attached to the plasma membrane via 
a glycosyl-phosphotidylinositol (GPI) anchor and interact with Ret of the same 
cell via a cis-binding.  GFRα paralogues has less than 50% amino acid identity, 
but all of them shared a similar conserved cysteine residue arrangement.  Like 
GFLs, the orthologues of all GFRα receptors can also be found in several 
vertebrates [5, 34]. 
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 GFRα organizational structure consists of three homologous cysteine-
rich domains with C-terminal extensions of different lengths [35, 36].  Direct 
chemical cross-linking and proteomic analyses of receptor-ligand interactions 
revealed key residues at the distal end of the N-terminus (residues 89-101 of 
12D1 of GFRα1) contacted Ret at multiple sites, which strongly suggest that 
the N-terminal of the domains are of high biological significance during Ret 
binding [37].  These domains (Domains 1, 2 and 3) have been shown to play 
different roles in the binding of GFLs and Ret.  Domain 2 (D2) has been 
shown to be involved in the binding of GFLs [31, 32, 38, 39]; while Domain 3 
(D3) acts to stabilize D2 during the binding of the ligands.  On the other hand, 
Domain 1 (D1) does not appear to play any role during the Ret binding of 
GFRα1 [40], and is not found in GFRα4 [35].  However, full length GFRα1 
has been shown to be more biologically active than D1 truncated mutants, 
suggesting that the D1 domain may actually contribute to the optimal function 
of  GFRα1, possibly via the stabilization of the interaction between GFRα1 
and GDNF [40].  The crystal structures of the domains have also been 
obtained from truncated forms of GFRα1 and GFRα3.  The crystal structure of 
the D3 of GFRα1 was the first to be determined and it was used to model D2 
and subsequently, the structure of D2/D3 of GFRα2 was successfully deduced 
[31]. 
 Ret on the other hand, was originally identified as an oncogene.  It is 
found to be activated by a re-arrangement of DNA in a 3T3 fibroblast cell line 
transfected with DNA taken from human lymphoma cells [41, 42].  It encodes 
a receptor tyrosine kinase (RTK), which is a single-pass transmembrane 
protein consisting of a cadherin-related motif and a cysteine-rich extracellular 
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domain.  Ret is by far the only RTK known to not bind its ligands directly, but 
requires co-receptors for its activation.  Oncogenic Ret activation by mutations 
or rearrangements has been shown to be involved in cancers like multiple 
endocrine neoplasia type 2 (MEN2A and MEN2B), medullary thyroid 
carcinoma (MTC) and papillary thyroid carcinoma (PTC) [43].  Moreover, Ret 
loss-of-function mutation is closely associated with Hirschsprung‟s disease 
[44].  
 Recently, the heterotetrameric complex of GDNF dimer interacting 
with the two GFRα1 D2 and D3 domains has been solved [45].  When 
compared to the heterotetrameric complex of the ART homodimer and the 
GFRα3-dimer [32], the GDNF-GFRα1 complex showed some similarities in 
the way the GFLs fingertips bind their respective receptor, and there are high 
similarities in the global structures of GFRα1 and GFRα3.  These structural 
studies laid down a framework for the structural basis of ligand-receptor 
interactions.  This therefore shows that all GFRα likely share similar structures 
but differ slightly in their respective binding sites of GFLs and the interaction 
sites with Ret.  Therefore it is not unreasonable to suggest that although the 
D1 domain of the GFRα does not appear to be important for Ret binding, the 
differences in its N-terminal sequences, found in multiple isoforms of GFRα, 
may be involved in modulating the interactions of GFLs with the other 
components of the receptor complexes.  These slight differences in the 
sequences possibly lead to the binding preference of each GFL in activating 
their respective GFRα in vitro; though the activation of the multi-component 
receptor system does show a certain degree of promiscuity in their ligand 
specificities (Figure 1.2) [33, 35, 38, 46, 47].  GDNF preferentially binds to 
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GFRα1, NTN to GFRα2, ART to GFRα3 and PSP to GFRα4.  The 
promiscuity is most prominent in NTN and ART, which have been reported to 
exhibit interaction with GFRα1; and GDNF, which interacts with GFRα2 and 
GFRα3 [48]. 
 In the nervous system, the expression patterns of GFRα and Ret are 
located in areas where neurons are responsive to innervations of GFLs [49-63].  
Although normally one of the GFRα are co-expressed with Ret, there are cases 
where there is a mismatch of the two components in some brain regions [17, 
49, 50, 54-56, 58, 64-66].  This Ret-independent GFRα expression is 
hypothesized to play a role in Ret activation in a non-cell-autonomous manner, 
via the capture of diffusible GFLs to present them in trans to neighbouring 
cells expressing Ret [67].  However, this mechanism is shown to be 
unnecessary for nerve regeneration and organogenesis in a transgenic mouse 
model [68].  Ret and GFRα expressions are generally low in the nervous 
system  [50, 51, 64, 68, 69] but they are regulated developmentally, where a 
peak in expression is seen in the  early  postanatal  life  [64, 68, 70-72].  
Changes  in  expressions  have  also  been  reported in cases of nerve 
transection [73, 74], excitotoxic insult [69, 75-77], ischemia [78-82] and 
epileptic seizures [50, 69, 83, 84], which is suggestive of the beneficial role of 
GFL signaling during nerve injuries.   
 It is also interesting to note that GFLs, in addition to their RET 
signaling pathway, are also known to exhibit Ret-independent 
signalingmechanisms, where they are found to  modulate  the  functions  of  
neural  cell  adhesion  molecules  (NCAM)  through GFRα bindings[85, 86].  
Furthermore, being a relatively new component of the neural signaling 
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pathways, there are studies suggesting that GFLs may well be involved in 
other Ret and NCAM independent signaling pathway, where they are found to 
be involved in the GDNF promotion of cortical GABAergic neuron 
differentiation and migration [87]; another study also suggests Heparansulfate 
proteoglycan syndecan-3 to be involved in GDNF signaling[88].  Recently, 
GDNF are also shown to signal through the other co-receptor, integrin β1 [89].  




Figure 1.2 GFL, GFRα and co-receptor interactions.  Schematic 
representation of interactions between GFLs and their receptors and co-
receptors.  The arrows denote the preferred ligand-receptor interactions while 
the broken arrows indicate cross-talks of GFLs with non-cognate GFRα.  GFL 
signal is transduced through interaction of ligand bound receptor GFRα, with 




1.3 GDNF receptor complex in neuronal biology 
Since the discovery of the roles of GDNF in promoting survival and 
differentiation of midbrain dopaminergic (DA) neurons and increasing the 
affinity of dopamine uptake of DA neurons [1], research on the roles of GFLs 
and the receptor complex on neuronal biology have been extensively 
conducted.  GDNF and NTN based gene therapies are currently in clinical 
trials for Parkinson‟s disease due to their potent neuroprotective and 
neurorestorative effects [90, 91].   
In addition to the roles of GDNF and NTN on neuroprotection of 
midbrain DA neurons and their therapeutic potential in Parkinson‟s disease, 
GDNF have also been shown to be involved in other psychiatric disorders.  
Alteration in the expression of GDNF was found to be associated with various 
neuropsychiatric diseases, including depression and schizophrenia, through 
impairing synaptic plasticity and deregulating DA neural circuits [92, 93].  
Gene polymorphism study recently shown the roles of GDNF polymorphisms 
in depression and anxiety [94].  NTN gene therapy was shown to improve 
motor function and survival of the striatal neurons in a rat model of 
Huntington‟s disease [95].         
 On top of their potential roles in neuronal diseases, GFLs have also 
been shown to play essential roles in normal neuronal development, 
neuroprotection, neurorestoration and other neuronal functions.  Recent 
studies have shown that GDNF is directly involved in the development of the 
enteric nervous system of the autonomic nervous system [96].  NTN was 
shown to be an essential neurotrophic factor for the development of 
parasympathetic neurons [97] while the roles of ART in sensory neurons are 
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widely studied [98-100].  NTN also appears to likely play a role in 
neuroplasticity in the regeneration of damaged neurons, where they are found 
to be up-regulated in the presence of neuronal damage or neuropathy [101].  
Furthermore, GDNF was found to induce neuronal excitability of midbrain 
dopaminergic neurons by potentiating the Ca(2+) channels or indirectly 
participate in the synaptic excitation in rat CA1 pyramidal neurons via the 
formation of DNSP-11 (also named BEP), a peptide derived from the 
translated sequence of GDNF [102, 103].    
With the discovery of a multitude of important functions of the GFLs, 
it is therefore imperative to continue to explore the profiles of the different 
actions of GDNF receptor complex in the development and function of 
neurons so as to provide a framework for a deeper understanding of the 
mechanistic actions of the respective GDNF interactions in the neurons.           
 
1.4 GDNF receptor complex in cancer  
Other than their function in neuron organogenesis and differentiation, 
GFLs were found to be involved in many other physiological functions.  This 
is achieved through a multi-component receptor complex consisting of GDNF 
family receptor alpha (GFRα), RET and NCAM as mentioned previously [93, 
104].  However, due to the fact that GDNF receptor complex is highly 
involved in the survival and protection of the neurons, their expressions and 
functions have to be tightly regulated, as any forms of alteration would likely 
lead to undesirable outcome, including cancer.   
During cancer development, cells are known to acquire similar 
biological capabilities, such as sustaining proliferative signaling, preventing 
11 
 
cell death, enabling immortality, promoting angiogenesis and inducing 
invasion and metastasis [105].  The growth factors and Receptor tyrosine 
kinases (RTKs), which are known to be the primary mediators of various 
cellular processes, including proliferation, differentiation, cell death and 
migration, are also found to play critical roles acquiring these biological 
capabilities of cancer [106].  RTKs have been reported to contribute to tumor 
progression through gene amplification, overexpression and mutation which 
lead to ligand-independent, constitutive active RTKs [107].  Moreover, 
aberrant RTK signaling can be achieved by the autocrine growth factor loop 
activation.  This mechanism could be observed when the expression of RTKs 
is deregulated in the presence of its respective ligand or the aberrantly 
expressed or the overexpression of the associated ligand [106].  In many 
tumours, overexpression of both RTK and its ligand has been reported [108].             
Studies have shown that GDNF, its receptor, GFRα1, and co-receptor, 
RET, are highly expressed in glioma specimens [109, 110].  Up to five times 
more GDNF has been found to be expressed in even the most dedifferentiated 
form of glioma samples as compared to normal brain [110].  These interesting 
observations have attracted the concern of researchers in studying the 
pathobiological roles of GDNF in glioma.  To date, GDNF have been found to 
be involved in migration and invasion [111-113], proliferation [114] and 
chemo-resistance [109] of glioma.   
Interestingly, GDNF as an oncogenic factor is not restricted to brain 
tumors.  GDNF receptor complexes have been shown to be involved in a 
variety of other cancers such as oral cancer [115, 116], pancreatic cancer [117-
119], lung cancer [119, 120], colorectal cancer [121, 122] and breast cancer 
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[123-125].  The GDNF receptor complex has been shown to play important 
roles in regulating proliferation, chemoresistance, migration and invasion of 
these cancers.     
With the prominence of cancer in the current medicinal field, it is 
therefore interesting to continue exploring the roles of GDNF and its possible 
intervention in order to gain insights into how GDNF signaling may play a 
part in cancer progression.   
 
1.5 Alternatively spliced isoforms of GDNF receptors  
 A recent emerging trend of this multi-component signaling system, 
consisting of GFRα, Ret and NCAM is that the specific combinatorial 
interactions of these components may contribute to the myriad of observed 
biological responses.  To add to the complexity, splice variants of each 
components of this further increase the intricacies of the signaling pathway. 
Alternative splicing is known to be prevalent in many mammalian genomes, 
which allows the production of polypeptides with diverse functions from a 
single gene.  An in-depth analysis of different human tissue and cell line 
transcriptomes by complementary DNA fragment deep sequencing showed 
92-94% of the human genes are alternatively spliced[126].  Furthermore, most 
of the conserved alternative splicing has been shown to occur in the central 
nervous system [127].  Indeed, multiple alternatively spliced variants of 
GFRα1 [52, 128, 129] and GFRα2 [130, 131] have been identified, and 
similarly, alternatively spliced isoforms of Ret [132, 133] and NCAM [134, 
135] have also been reported.  The existence of multiple alternatively spliced 
variants of the GFLs, GFRα and other co-receptors therefore allowed these 
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limited number of ligands and receptors to generate large numbers of 
combinations and may give rise to the observed pleiotropic effects.   
 The  alternatively  spliced  isoforms  of  GFRα1  have  been  shown  to  
be differentially expressed in different tissues [61] and regulated differentially 
during kidney development [136].  GFRα1 isoforms were also shown to 
exhibit distinct functions in regulating neurite outgrowth and glioma biology 
[113, 137].  The ligand activation of GFRα2 isoforms was shown to also 
differentially activate AKT and MAPK (ERK1/2) signaling, and regulate 
distinct early response genes.  Furthermore, both GDNF and NTN were 
demonstrated to induce neurite outgrowth through the activation of GFRα2a 
and GFRα2c, but not GFRα2b.  GFRα2b activation conversely inhibited 
neurite outgrowth that was induced by GFRα2a, GFRα2c, GFRα1a and 
retinoic acid.  The mechanism underlying the inhibitory effectGFRα2b is 
RhoA-dependent [62].  This finding therefore provides early evidence that 
shows the dominant inhibitory activity of GFRα2b on neurite outgrowth and 
underlines the distinct signaling mechanisms of alternatively spliced GFRα 
isoform activation.  It will thus be of interest to know whether GFRα receptor 
isoforms may also show functional differences in other physiological and 
neuritogenic functions.  
 The Ret receptor isoforms also possess functional pleiotropy.  The two 
major RET isoforms, Ret9 and Ret51, with their primary differences in their 
C-termini, were initially cloned from a human neuroblastoma cell line [138].  
Chimeric mouse-human mono-isoformic Ret mice were generated in order to 
understand the significance of each isoform in vivo.  These isoforms have been 
shown to have striking functional differences in their roles in embryo 
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development and organogenesis [139].  Mice lacking Ret51 was shown to 
develop normally with no apparent defect while mice lacking Ret9 was found 
to have kidney hypodysplasia and defects in enteric innervation.  Similar 
observation has been done in Ret knockout mice.  In addition, Ret9 but not 
Ret51 is experimentally shown to be the factor that rescues the phenotype of 
Ret knockout mice.  Interestingly however, Ret51 but not Ret9 is the one 
being shown to promote the tubulogenesis and survival of mouse inner 
medullary collecting duct cells in contrast [133].  These findings suggested the 
existence of isoform specific roles in embryo development and organogenesis.  
Whether or not these isoform further interact with GFRα isoforms to produce 
another layer of complexity in GDNF signaling is therefore an interesting area 
of study.  
 It is now clear that the diverse cellular and molecular effects of GDNF 
signaling can largely be attributed to the differential expressions and distinct 
functions of GDNF receptor isoforms.  And thus, receptor isoforms that are 
largely understudied now such as GFRα1a and GFRα1b warranted much 
attention in assessing whether they play any distinct roles in other 
physiological functions and disease biology.    
 
1.6 Objectives of the Study 
 GDNF and NTN play essential roles in various neuronal functions and 
are involved in various diseases including cancer.  They transduce signal 
through a compound multi-component receptor complex comprising GFRα 
and co-receptors Ret and/or NCAM.  GFRα isoforms produced by alternative 
15 
 
splicing of the mRNA are differentially regulated and have distinct functions 
in neuronal biology as well as cancer progression.     
 In order to gain insight of the roles of the GDNF receptor complex in 
neuronal differentiation and breast cancer biology, this thesis further explores 
the combinatorial interactions of different GFLs and receptors by studying the 
effect of GDNF and NTN on the regulation of GDNF receptor complex gene 
expression and neuronal profile during neuronal differentiation using Ntera2 
cell model and examining the effect of GDNF and NTN stimulation and 




CHAPTER 2  
GDNF AND NTERA2 DIFFERENTIATION 
 
2.1 Background 
 Injury related neuro-disorders and neurodegenerative diseases are 
gradually becoming prevalent in the world‟s aging population.  With treatment 
for such diseases being limited, cell replacement therapy, where dead or 
damaged neurons were replaced with new healthy ones to restore the functions 
of the damaging site, has since gained widespread attention following the first 
success in neuron implantation experiment using rat model [140].  The hope 
here is that one day it will be possible to replace essential parts of the nervous 
system and subsequently improve the quality of life of patients.     
 Due to the unique capacity of neural stem/progenitor cells (NSC/NPC) 
in their self-renewal and pluripotency, they therefore hold the potential to be 
used in cell replacement therapies.  The process of NSC/NPC differentiation 
and lineage specification is tightly regulated, driven by temporal changes of 
the signaling ligands, cell surface receptors as well as transcriptional 
regulators.  GDNF was reported to induce NSC/NPC survival and 
differentiation into multiple neuronal lineages including dopaminergic (DA) 
neurons and motor neurons [141, 142].  However, the involvement of specific 
GDNF receptors and co-receptors and the underlying mechanism during these 
processes remain to be elucidated.  Furthermore, it is interesting to study 
whether NTN functions similarly as GDNF during NSC/NPC differentiation 
and neuronal lineage specification since GFLs has been reported to carry 
ligand specific function both in vitro and in vivo.   
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Ntera2 cell (NT2) is a widely studied pluripotent human embryonic 
teratocarcinoma stem cell line which was found to have similar genetic and 
epigenetic profiles as human embryonic stem cell (hESC) [143].  Since 
procedures for culturing hESC lines are very demanding, NT2 which can be 
handled with relative ease has been widely used to examine the process of the 
transition from  neuro-progenitor state to differentiated neurons [143] and 
hence it has become an established model to study human neural development 
[144-147].  In addition, in a recent clinical trial, NT2 has also been used as a 
replacement therapy for stoke and implanted NT2N neurons derived from NT2 
can survive for more than two years in human brain without any deleterious 
effects [148].  This encouraging finding showed that NT2 can potentially be 
used as a source of cells for cell replacement therapies.   
 NT2, with pluripotency properties, is able to differentiate into glial, 
oligodendrocytic and neuronal cells according to the respective stimuli [143, 
149].  It is well known that after treatment by retinoic acid (RA), NT2 will  
differentiate into neurons [144, 150]; and this neuronal differentiation induced 
by RA in high density suspension culture was reported to be highly 
reproducible [151].  Networks of neuronal genes were found to be regulated 
temporally and spatially during in vivo neurogenesis of neuroepithelial 
precursors [152].  The expression of GDNF receptors, including GFRα1 and 
GFRα2, were reported to be altered during neuro-steroid 22R-
hydroxycholesterol treatment [153] and PA6 feeder layer induced NT2 
differentiation [143].  In addition, GDNF stimulation was found to inhibit NT2 
proliferation[154], suggesting the involvement of GDNF receptor complex in 
the differentiation of NT2 cells.  Just recently, the regulation of GDNF 
18 
 
receptor complex and the involvement of GFLs during NT2 differentiation had 
been examined using suspension culture [155].  In order to further study the 
roles of GDNF receptor complex in neuronal differentiation and neuronal 
lineage specification, a well-controlled monolayer adherent culture might 
serve as a better model as compared to the suspension culture with issues of 
aggregate colonies.  Hence, it is therefore imperative to study the regulation of 
GDNF receptor system and the profile of neuronal lineages in adherent culture 
in order to establish a model for the study of GDNF receptor system in 
neuronal differentiation and neuronal lineage specification.           
In addition to the involvement of biochemical factors, signaling 
pathways and transcriptional system; biophysical properties of the culturing 
environment in regulating cell lineage differentiation have now been shown to 
be important for cell differentiation.  In year 2006, Engleret al. had first shown 
the powerful effect of tissue-level elasticity on stem cell lineage specification.  
In the study, soft, stiffer and rigid extracellular matrices were shown to be 
neurogenic, myogenic and osteogenic respectively.  [156]  Since then, many 
studies have been carried out in order to understand the roles of culturing 
environment in cell differentiation [157-159].  However, the effect of culturing 
environment on the extent of NT2 differentiation remains to be elucidated.   
In this chapter, the gene regulation of GDNF receptor complex and 
markers of different neuronal lineages were examined during NT2 
differentiation driven by RA as well as GFLs stimulation.  Furthermore, the 
effects of different culturing methods on mRNA regulation of neuronal 
markers as well as GDNF receptor system were investigated.  Having a clearer 
picture of the regulation of GDNF receptor system and its effects on neuronal 
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marker expressions and the resulting changes in GDNF receptor system 
expression in different culture system, could provide insights into how 
neuronal differentiation were regulated.  This would help in designing studies 
to understand and fine-tune the process of GDNF receptor system mediated 




2.2.1 Regulation of GDNF family receptors and co-receptors during RA 
induced NT2 differentiation 
 NT2 differentiation was induced with RA in suspension or adherent 
culture for a period of 24 days.  Consistent with previous reports, NT2 cells 
continued to proliferate while cells treated with RA were found to terminate 
proliferation [155].  In suspension culture, NT2 cells without stimulation 
formed aggregate colonies with a different surface cell density as compared to 
RA treated cells (Figure 2.1A).  In adherent culture, control NT2 cells 
remained an epithelial-like morphology while cells stimulated with RA 
adopted neuronal morphology over time (Figure 2.1B).   
 In order to establish a model to study the roles of GDNF receptor 
complex in NT2 differentiation, an adherent culture might serve as a better 
model as compared to a suspension culture because of better control of 
culturing conditions in a monolayer adherent culture where suspension 
cultures showed different sizes and densities of aggregate colonies.  Hence, 
the gene expression of GDNF receptor system was quantified in both 
suspension and adherent culture in order to find out whether the receptors and 
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co-receptors were regulated similarly in adherent culture as compared to the 
suspension culture.  Similar to the suspension culture, the mRNA expression 
of GFRα1 and NCAM was up-regulated during RA stimulation while Ret was 
found to be down-regulated initially and returned to the control level gradually 
(Figure 2.2A).  Interestingly, GFRα2 gene was found to be up-regulated after 
10 days of stimulation in suspension culture while this gene was not up-
regulated throughout the 24 days of stimulation in adherent culture (Figure 
2.2).   
 Generally, the genes of the GDNF receptor complex were found to be 
regulated with similar trends in suspension and adherent culture.  These results 
suggested that both suspension and adherent culture might go through a 
similar process of regulation on GDNF receptor complex during RA treatment.  
Thus, adherent culture was selected for the study of the roles of GDNF 










Figure 2.1 Differentiation of NT2 cells induced by retinoic acid.  NT2 cells 
were treated in suspension or adherent culture with or without 10 μM RA over 
a period of 24 days.  (A) Representative images of control and RA stimulated 
cells in suspension culture.  (B) Representative images of control and RA 
stimulated cells in adherent culture.     
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Figure 2.2 Regulation of GDNF receptors and co-receptors during RA 
induced NT2 differentiation.  NT2 cells were stimulated with RA in 
suspension (A) or adherent (B) culture over a period of 24 days and the 
regulation of mRNA expression level of GFRα, Ret and NCAM were 
quantified and presented as fold changes compared to non-stimulated control 
samples after normalized to the geometric means of the relative values of 





2.2.2 Neuronal differentiation of NT2 cells was differentially regulated 
by GFLs stimulation 
 To examine the effect of GFL signaling on neuronal differentiation, 
NT2 cells were stimulated with RA for 7 days before treated with GFLs alone 
or combinations of RA and GFLs and the gene expression of GDNF receptors 
and neuronal markers were quantified (Figure 2.3).  Seven-day RA-treated 
NT2 cells were chosen because the gene expression of GFRα1 and NCAM 
would have been up-regulated while the expression of Ret and GFRα2 were 




Figure 2.3 Schematic representation of the experimental procedure of 
NT2 differentiation.  NT2 cells treated with 10 μM RA for 7 days before 
stimulated with RA, RA + GDNF, RA + NTN, GDNF alone or NTN alone for 




The effect of different stimulations on the gene regulation of GDNF 
receptors and co-receptors was examined.  Interestingly, GFRα1 gene 
expression was significantly down-regulated (Figure 2.4A) while the gene 
expression of GFRα2 was significantly up-regulated (Figure 2.4B) when the 
cells were incubated with only GDNF or NTN alone as compared to the RA 
treated cells.  While different stimulations possessed little and non-significant 
24 
 
effect on Ret gene expression (Figure 2.4C), GDNF or NTN stimulation alone 
significantly reduced the expression of NCAM as compared to the RA treated 
cells (Figure 2.4D).  These results suggested that RA signaling was important 
for the up-regulation of GFRα1 and NCAM expression and down-regulation 
of GFRα2 expression during differentiation.    
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Figure 2.4 Gene expression of GDNF receptors and co-receptors was 
differentially regulated by GDNF and NTN.   The effect of different ligand 
treatments on the expression of GFRα1 (A), GFRα2 (B), Ret (C) and NCAM 
(D) were quantified using real-time qPCR.  The results were presented as fold 
changes compared to non-stimulated control samples after normalized to the 
geometric means of the relative values of RPL19 and RPL3.  ** p<0.01, 







 We further examined the effects of GFLs in regulating the expression 
of neuronal marker mRNAs.  Different ligand stimulations were found not to 
significantly regulate the expression of neuronal markers, Tubb3 and NEFH, 
as compared to the RA treated cells (Figure 2.5).  The regulation of the 
expression of DA markers was also quantified.  It is found that while the co-
stimulation of RA and GFLs exerted little regulating effect on the six RA 
regulated genes,  stimulation  with either GDNF or NTN showed an up-
regulation of three of the RA regulated genes  while down-regulating the other 
three  when compared to the RA treated cells (Figure 2.6).  The expression of 
Nurr1 (Figure 2.6A), DAT (Figure 2.6B) and EN1 (Figure 2.6C) was 
significantly down-regulated while the expression of GIRK2 (Figure 2.6D), 
Otx2 (Figure 2.6E) and Msx1 (Figure 2.6F) was significantly up-regulated 
after a switch from RA signaling to GFL signaling.  The effect of GDNF and 
NTN stimulations did not have any significant difference on the regulation of 










Tubb3 Form microtubules, involved in neurogenesis, axon guidance and 
maintenance 
NEFH Form neurofilaments 
 
Figure 2.5 Different ligand treatment did not significantly regulate the 
expression of neuronal markers.  The effect of different ligand treatments on 
the expression of Tubb3 (A) and NEFH (B) were quantified using real-time 
qPCR.  The results were presented as fold changes compared to non-
stimulated control samples after normalized to the geometric means of the 
relative values of RPL19 and RPL3.  The functions of these genes are 
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Nurr1 Transcription factor specific to DA neurons 
DAT Recycle dopamine 
EN1 Transcription factor specific to DA neurons 
GIRK2 Potassium channel in SPnc neuron 
Otx2 Transcription factor specific to forebrain DA neurons 
Msx1 Transcription factor specific to DA neurons 
 
Figure 2.6 Gene expression of DA markers was differentially regulated by 
GDNF and NTN.   The effect of different ligand treatments on the expression 
of Nurr1 (A), DAT (B), EN1(C), GIRK2 (D), Otx2 (E) and Mash1 (F) were 
quantified using real-time qPCR.  The results were presented as fold changes 
compared to non-stimulated control samples after normalized to the geometric 
means of the relative values of RPL19 and RPL3.  ** p<0.01, analysed using 
One-way ANOVA, Bonferroni post-test.  The functions of these genes are 





 Similarly, the mRNA expression levels of other neuronal lineage 
markers were also quantified by real-time qPCR.  As what was observed in the 
regulation of DA markers, co-stimulation of RA and GFLs also exerted little 
effect on the expression of other neuronal lineage markers.  Different 
stimulations were found not to significantly regulate the transcript expression 
of markers for glutamatergic neurons, including VGLUT (Figure 2.7A), GLS-
1 (Figure 2.7B) and GLS-2 (Figure 2.7C).  For markers of cholinergic neurons, 
AChE expression was not significantly regulated by the different ligand 
stimulations (Figure 2.7D) while the expression of ChAT was significantly 
down-regulated by GDNF stimulation (Figure 2.7E) and VAChT was 
significantly down-regulated by NTN stimulation (Figure 2.7F) as compared 
to RA treated cells.  Interestingly, the expression of serotonergic neuron 
marker, Mash1 was significantly down-regulated (Figure 2.7G) while the 
expression of Islet1, a marker for motor neurons, was significantly up-
regulated (Figure 2.7H) when the stimulation was switched from RA into 
GDNF or NTN.  These results indicated that different ligand stimulations were 
capable of affecting the differentiation profile of NT2 cells.  Hence, this might 
be a suitable model for the investigation of the mechanisms underlying 
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I 
Gene Neuronal Lineage Function 
VGLUT Glutamatergic neuron Uptake of L-glutamate 
GLS-1 Glutamatergic neuron Generate glutamate from glutamine 
GLS-2 Glutamatergic neuron Generate glutamate from glutamine 
AChE Cholinergic neuron Hydrolyze acetylcholine 
ChAT Cholinergic neuron Synthesize acetylcholine 
VAChT Cholinergic neuron Transport acetylcholine into vesicles 
Mash1 Serotonergic neuron Transcription factor for serotonergic 
differentiation 




Figure 2.7 Effect of different ligand stimulation on gene expression of 
other neuronal lineage marker genes.  The effect of different ligand 
treatments on the gene expression of markers for glutamatergic neurons (A, B, 
C), cholinergic neurons (D, E, F), serotonergic neurons (G) and motor neurons 
(H) were quantified using real-time qPCR.  The results were presented as fold 
changes compared to non-stimulated control samples after normalized to the 
geometric means of the relative values of RPL19 and RPL3.  ** p<0.01, 
analysed using One-way ANOVA, Bonferroni post-test.  The functions of 
these genes are summarized in I.    
 
 
2.2.3 Effect of culturing methods on expression of GDNF receptor and 
co-receptors and NT2 differentiation 
 In order to study the effect of culturing methods on NT2 differentiation 
and the regulation of the expression of GDNF receptor complex, NT2 cells 
were seeded directly on cell culture dish, on a layer of collagen (2D Substrate) 
or in a layer of collagen (3D Substrate) before stimulated with  or without RA 




Figure 2.8 Schematic representation of the experimental procedure using 
collagen.  NT2 cells seeded directly on cell culture dish (Ctrl), on a layer of 
collagen (2D Substrate) or in a layer of collagen (3D substrate) before treated 






 The effect of different culturing method on RA induced regulation of 
neuronal marker mRNA expressions was examined.  No significant difference 
of NEFH gene regulation induced by RA stimulation could be observed in 
different culturing conditions (Figure 2.9A).  Interestingly, when the cells 
were stimulated on or in a layer of collagen, the expression of Tubb3 was 
significantly up-regulated compared to the cells stimulated on cell culture dish 
(Figure 2.9B).   
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Figure 2.9 Regulation of neuronal marker gene expression when treated 
by RA in different culturing conditions.   RA induced regulation of the 
expression of NEFH (A) and Tubb3 (B) was quantified using real-time qPCR.  
The results were presented as fold changes compared to untreated control 
samples after normalized to the geometric means of the relative values of 
RPL19 and RPL3.  ** p<0.01, analysed using One-way ANOVA, Bonferroni 




 The effect of culturing methods on gene regulation induced by RA 
stimulation was further investigated in the gene regulation of DA markers and 
marker of motor neurons.  There was no significant difference in the gene 
regulation of Nurr1 (Figure 2.10A).  The gene expression of DAT was found 
to be up-regulated when the cells were treated with RA on or in a layer of 
collagen compared to those stimulated on the cell culture dish (Figure 2.10B).  
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Unexpectedly, the gene expression of TH, a commonly used DA marker, 
which was rarely expressed throughout the 24-day RA stimulation in the 
previous experiment, was found to be up-regulated when they were treated 
with RA on or in a layer of collagen (Figure 2.10C).  Interestingly, the 
expression of Islet1, the maker for motor neuron, which was found to be up-
regulated when stimulated with GDNF or NTN in the previous experiment 
(Section 2.2.2, Figure 2.7H), was significantly down-regulated when the cells 
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Figure 2.10 Regulation of gene expression of markers for DA and motor 
neuron when treated by RA in different culturing conditions.   RA induced 
regulation of the expression of DA markers (A, B, C) and marker for motor 
neurons, Islet1 (D) was quantified using real-time qPCR.  The results were 
presented as fold changes compared to untreated control samples after 
normalized to the geometric means of the relative values of RPL19 and RPL3.  





 The effect of different culturing method on the gene regulation of 
GDNF receptors and co-receptors after RA stimulation was examined.  There 
was no significant difference in the gene expression of GFRα1, GFRα2 and 
Ret of RA stimulated NT2 cells culturing in different methods (Figure 2.11A, 
B, C).  Interestingly, NCAM was significantly up-regulated when stimulated 
with RA in a layer of collagen compared to those stimulated on cell culture 
dish or on a layer of collagen (Figure 2.11D).   
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Figure 2.11 Gene expression of GDNF receptors and co-receptors was 
differentially regulated when treated by RA in different culturing 
conditions.   RA induced regulation of the expression of GFRα1 (A), GFRα2 
(B), Ret (C) and NCAM (D) in different culturing conditions was quantified 
using real-time qPCR.  The results were presented as fold changes compared 
to untreated control samples after normalized to the geometric means of the 
relative values of RPL19 and RPL3.  ** p<0.01, analysed using One-way 








 In this study, NT2 cells stimulated as an adherent culture was shown to 
be a potential model for the study of the roles of GDNF receptor system in 
differentiation of neurons and neuronal lineage specification.  The GDNF 
receptors, GFRα1 and GFRα2, as well as the co-receptors, Ret and NCAM, 
were found to be expressed endogeneously in NT2 cells and differentially 
regulated during RA treatment in adherent as well as suspension culture.  Due 
to the ease of control when dealing with monolayer adherent culture compared 
to aggregate colonies in suspension culture, adherent culture of NT2 was 
therefore selected as a model to study the roles of GDNF receptor system in 
differentiation of neurons and neuronal lineage specification.    
 NT2 cell line, which was shown to share high similarity in genetic and 
epigenetic profiles with hESC and with pluripotency properties, is a “surrogate” 
stem cell model well characterized for in vitro neurogenesis study.  NT2 cells 
can be propagated without defined media or feeder cells rapidly and easily 
compared to hESC.  Due to all of these beneficial properties, NT2 cells are 
widely used in cell cycle regulation and neuronal differentiation study, 
including the study of neuronal lineage specification of DA and motor neurons 
[160, 161].  Although NT2 cells were used in several studies to examine DA 
neuron differentiation, the roles of GFLs, neurotrophic factors that are known 
to have neuroprotective and neurorestrorative effect on DA neurons, are still 
unclear.  It is therefore noteworthy to find out whether the GDNF receptor 
system plays a role in NT2 differentiation and neuronal lineage specification 
using an adherent NT2 culture model.   
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 Unlike the use of defined media with several growth factors, feeder 
cells or feeder layer conditioned media, RA treatment is a highly efficient and 
reproducible model to study the differentiation of NT2 cells [155].  The NT2 
cells were stimulated with RA in high density suspension culture or in 
monolayer adherent culture to induce differentiation and the gene regulation of 
the GDNF receptors, GFRα1 and GFRα2, as well as the co-receptors, Ret and 
NCAM over time was quantified.  The regulation of GFRα1, Ret and NCAM 
transcripts of RA stimulated NT2 cells in suspension and adherent culture is 
similar.  Interestingly, unlike the suspension culture, the mRNA expression of 
GFRα2 in adherent culture was found to remain low and was not up-regulated 
throughout 24 days of stimulation.  These results suggested that NT2 adherent 
culture might serve a better model to study the roles of GFRα1 in neuronal 
differentiation with minimal effect from the presence of GFRα2. 
   GFLs application after RA stimulation was found to not significantly 
affect the gene expression of most of the neuronal markers; but significantly 
altered the expression of specific neuronal lineage markers when compared to 
RA stimulation and RA+GFL co-stimulation.  These results suggested that 
GFLs application after RA stimulation might direct the differentiation of NT2 
cells into specific neuronal lineages instead of induce more differentiation of 
NT2 cells into neurons.  Interestingly, when GDNF or NTN was used to 
stimulate the cells after RA treatment, most of the gene expression of early 
DA markers, including Otx2 and Msx1 [160], was found to be up-regulated 
while the expression of markers for post-mitotic DA precursor and mature DA 
markers, such as Nurr1 and DAT [160], was found to be down regulated as 
compared to RA treated cells.  These results suggested that the switch of 
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stimulation from RA into GFLs might delay the onset of NT2 differentiation 
into mature forms of DA neurons.  Besides markers for DA neurons, the 
switch in stimulation from RA to GFLs was found to reduce the expression of 
Mash1, the marker for serotonergic neurons and some of the markers for 
cholinergic neurons.  Importantly, Islet1, the marker for motor neuron was 
found to be up-regulated after the switch in stimulation from RA to GFLs, 
suggesting that GDNF and NTN stimulation might preferentially direct the 
neuronal differentiation into motor neurons.  Notably, not all markers for all 
neuronal lineages were found to be differentially regulated by different ligand 
stimulations.  No significant difference was found in the gene expression of 
markers for glutamatergic neurons when different ligand stimulation was used 
to induce NT2 differentiation.   
 The effect of culturing method on NT2 differentiation and GDNF 
receptor system expression was also examined in this study.  Soft 
microenvironment has been reported to induce differentiation of mesenchymal 
stem cells and human pluripotent stem cells into neurons [156, 158].  In this 
study, the gene expression of Tubb3 were also found to be up-regulated in 
cells stimulated with RA on or in a layer of collagen as compared with those 
stimulated directly on cell cultured dish.  Notably, the gene expression of 
Nurr1 was not significantly regulated, the gene expression of DAT was found 
to be up-regulated when NT2 cells were treated with RA on or in a layer of 
collagen.  It is noteworthy that the expression of TH, a DA marker which was 
rarely expressed in NT2 cells throughout the 24-day RA stimulation study, 
was found to be up-regulated in just 7 days when the cells were stimulated 
with RA on or in a layer of collagen.  These results indicated that NT2 cells 
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could more readily be differentiated into DA neurons when the cells were 
cultured on or in a layer of collagen.  Surprisingly, although neuronal markers 
were found to be up-regulated when the cells were stimulated in or on a layer 
of collagen compared to those stimulated directly on the cell culture dish, 
Islet1, the markers for motor neuron was found to be significantly down-
regulated.  This result suggested that the culturing method might have driven 
the neuronal differentiation away from motor neurons into other neuronal 
lineages.  This is a novel observation that culturing environment could 
differentially regulate the differentiation of NT2 into specific neuronal 
lineages.  These data, together with the data obtained above, provided a clearer 
picture of how NT2 cells were differentiated into specific neuronal lineages 
and will be useful for designing a more focused differentiation protocol in 
driving neuronal differentiation into specific neuronal lineages.      
 The gene regulation of GDNF receptors and co-receptors were also 
quantified in cells differentiated in different culturing conditions.  No 
significant regulation could be observed in the expression of GFRα1, GFRα2 
and Ret transcripts when the cells were stimulated on or in a layer of collagen 
compared to those stimulated directly on cell culture dish.  Interestingly, the 
expression of NCAM was found to be significantly up-regulated in RA 
stimulated cells cultured in a layer of collagen as compared to those cultured 
directly on cell culture dish and on a layer of collagen.  This result suggested 
that cells cultured on or in a layer of collagen might react differently to the 
stimulation.  Since NCAM was differentially regulated on or in a layer of 
collagen, it is reasonable to hypothesize that neuronal differentiation and 
neuronal lineage specification will be differentially regulated when GFLs are 
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used to induce differentiation of NT2 cells cultured on or in a layer of collagen.  
Further studies to investigate how GDNF receptor system interacts with the 
culturing environment to regulate NT2 differentiation and neuronal lineage 
specification should be performed in the future.      
 In conclusion, this study demonstrated the regulations of GDNF 
receptor system and the effect of different ligand stimulations as well as 
culturing methods in neuronal differentiation and neuronal lineage 
specification of NT2 cells.  Based on these data and observation, further 
studies could be designed in more focused paradigms to differentiate NT2 into 
specific neuronal lineages and study the roles of GDNF receptor system in 





CHAPTER 3   
GDNF AND BREAST CANCER 
 
3.1 Background 
Breast cancer is one of the most commonly diagnosed cancers 
worldwide and the most frequent cancer diagnosed in women [162].  
According to the GLOBOCAN 2008 estimates, 1.38 million new breast cancer 
cases (23% of all new cancer cases) were diagnosed in 2008.  Although the 
mortality rate of breast cancer is relatively low, it is still the fifth cause of 
death from cancer in general and the most common cause of cancer death in 
women.  [162] 
In the St. Gallen International Expert Consensus Report 2011, breast 
cancer samples were proposed to be classified according to their endocrine 
responsiveness [163].  Breast cancer samples could be classified into estrogen 
receptor (ER), progesterone receptor (PR), human epidermal growth factor 
receptor-2 (HER2) and Ki-67 based on their expression of those growth factor 
receptors.  This classification is proposed to aid in the selection of the 
appropriate chemotherapy for breast cancer patients [164].  It is reported that 
approximately 70% of human breast cancer samples are ER positive [165].  
ER activation was found to enhance cell proliferation and survival [166, 167].  
In order to inhibit estrogen receptor and treat breast cancer, estrogen pathway 
signaling is usually inhibited by blocking the conversion of estrogens from 
androgens using aromatase inhibitors or the use of antagonist for estrogen 
receptors, including tamoxifen[168].  However, the beneficial effects of such 
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endocrine therapies are ineffective when the tumours develop 
chemoresistance[168]. 
GDNF receptor complex has been well studied in neurobiology and 
their roles in various cancers have also gained attention.  The GDNF receptor 
complex has been shown to play important roles in regulating proliferation, 
chemoresistance, migration and invasion of many cancers as mentioned in the 
literature review (Section 1.4).  Recently, expression level of GFRα1 and Ret 
was found to be up-regulated in human breast cancer samples [125, 169], one 
of the most common cancers diagnosed in women [170].  Hence, it is 
interesting to examine whether GDNF and NTN play significant roles in 
human breast cancer through the activation GFRα1 and Ret.   
MCF7 cell, an ER positive breast cancer cell line widely used in breast 
cancer studies [171], was previously found to express GFRα1 and Ret and 
therefore has been used to study the roles of GDNF receptor complex in breast 
cancer cell biology [123, 125, 172].  What is not known is the contribution of 
alternatively spliced GFRα1 and Ret isoforms (Section 1.5) in the cell biology 
of MCF7.  Over the years, the roles of GDNF signaling in proliferation, 
migration and chemoresistance of human breast cancer cells began to be 
unravelled, especially the involvement of Ret in chemoresistance[123, 125, 
168, 172-174].  Whether GFRα1 plays a role in these breast cancer functions 
remains largely uncertain [172, 174].  Furthermore, NTN, the other GFL, was 
found to be associated with several cancers including glioma[109], medullary 
thyroid cacinoma[175] and colon cancer [176], the role of NTN in breast 
cancer biology has yet to be  examined.             
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This part of the study therefore aimed to gain a better understanding of 
GDNF or NTN interaction with the components of the receptor complex in 
breast cancer biology using the MCF7 cell model.  GDNF receptor complex 
was first profiled, and the effects of GDNF and NTN were tested on cell 
survival, proliferation, and during treatment with tamoxifen.  These 
experiments aimed to provide some novel insights into the involvement of 




3.2.1 Expression of GFLs and their receptors in MCF7 human breast 
cancer cells 
 The expression levels of two GFLs (GDNF and NTN), their cognate 
receptors (GFRα1 and GFRα2) and co-receptors (Ret and NCAM) were 
quantified in MCF7 cells using real-time qPCR (Figure 3.1A).  GFRα1, Ret 
and NTN were expressed in MCF7 human breast cancer cells while GFRα2, 
NCAM and GDNF transcripts were below detection limit.  Interestingly, when 
GFRα1 isoforms were quantified, both GFRα1 isoforms were expressed and 
GFRα1b were found to be expressed in a much higher level compared to 










Figure 3.1 Expression of GFLs and their receptor complexes in MCF7 
breast cancer cells.  The mRNA expression levels of GDNF family of ligands, 
receptors, co-receptors (A) and GFRα1 isoforms (B) were quantified using 
real-time PCR and normalized to GAPDH.  The results were presented as 
mean ± SD.    
 
 
3.2.2 The effect of GDNF and NTN stimulations in MCF7 
 The involvement of the GDNF receptor complex in breast cancer 
biology was first examined on the MCF7 cell viability by the stimulation of 
GDNF and NTN.  Both GDNF and NTN stimulation were found to 
significantly increase cell viability (Figure 3.2).  However, they did not show 
any significant effect on anchorage-independent proliferation (Figure 3.3).  
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During tamoxifen treatment, both GDNF and NTN significantly increased 
viable cells in MCF7 (Figure 3.4).  In accordance with what was shown in 
Figure 3.2, GDNF and NTN stimulation significantly increased number of 
viable cells treated without tamoxifen treatment.   
  
    
 
Figure 3.2 GDNF and NTN stimulations significantly increased viable 
cells.  MCF7 cells were stimulated with 100 ng/ml of GDNF or NTN for 96 hr 
and viable cells were quantified.  The fold change of viable cells was 
presented as Mean ± SEM of three independent experiments with three 







Figure 3.3 GDNF and NTN stimulation did not significantly affect 
anchorage-independent proliferation.  MCF7 cells were seeded on 
polyHema coated plate and stimulated with 100 ng/ml of GDNF or NTN 
immediately.  Viable cells were quantified after the cells were stimulated for 
96 hr.  The fold change of viable cells was presented as Mean ± SEM of three 




Figure 3.4 GDNF and NTN stimulations increased viable cells in 





 M tamoxifen with or without 100 ng/ml of GDNF or NTN for 6 
days.  The fold change of viable cells was presented as Mean ± SEM of three 
independent experiments with three biological replicates. * p<0.05, ** p<0.01, 






3.2.3 Specific knockdown of GFRα1 isoforms in MCF7 using siRNA 
 In order to study the specific functions of GFRα1 isoforms, siRNA 
duplexes were designed to specifically knockdown GFRα1a or GFRα1b in 
MCF7 cells, according to the method previously described [113].  Briefly, 
siRNA duplexes overlapping exons were designed since there is no distinctive 
nucleotide sequence difference in GFRα1b and GFRα1a.  Three siRNA 
duplexes (GFRα1b #1, #2 and #3) were designed to target exon 4 and 6 of 
GFRα1b, with 4, 6, and 9 nucleotides within exon 6 respectively (Figure 3.5A).  
Although all siRNA duplexes efficiently reduced the expression of GFRα1b 
and showed significant discrimination between GFRα1a and GFRα1b, siRNA 
#2 was chosen for subsequent studies because it had lowest off-target effect on 
GFRα1a mRNA expression (Figure 3.5B).   
 Similarly, two siRNAs duplexes (GFRα1a #1 and #2) were designed 
with sequences overlapping exon 4 and 5 of GFRα1a, which contained 12 and 
14 nucleotide within exon 5 respectively (Figure 3.5A).  Both of them 
significantly knocked down GFRα1a expression and exhibited significant 
discrimination between GFRα1a and GFRa1b.  GFRα1a #1 siRNA was 
selected for subsequent studies as it did not significantly affect GFRa1b 












Figure 3.5 Knockdown of GFRα1a and GFRα1b using isoform-specific 
siRNA.  (A) Graphic representation of exon organizations and positions of 
isoforms-specific siRNAs of GFRα1a and GFRα1b.  (B) Specific knockdown 
of GFRα1 isoforms by siRNAs.  Expression level of GFRα1a and GFRα1b 
were quantified using real-time qPCR and normalized to geometric means of 
the relative quantities of RPL19 and RPL3.  Expressions of GFRα1a and 
GFRα1b were efficiently knocked down by all designed siRNAs.  GFRα1a #1 
and GFRα1b #2 siRNAs were selected for subsequent studies according to 
their knock down specificity and lack of undesirable effects.  Luciferase 
siRNA was used as the negative control.  The results were presented as mean 








3.2.4 Knockdown effect of GFRα1a, GFRα1b, GFRα1 and Ret siRNA on 
gene and protein expression in MCF7 cells  
 Before the siRNAs were used to study the roles of GFRα1 and Ret in 
breast cancer biology, the knockdown effect of the designed GFRα1a and 
GFRα1b siRNAs as well as the commercially available GFRα1 and Ret 
siRNAs were validated based on the gene expression and protein expression 
study.  All siRNAs were shown to efficiently knock down their corresponding 
target mRNAs (Figure 3.6).  Since GFRα1 isoform specific antibodies are not 
available due to their high sequence similarity, the knockdown effect of the 
siRNAs could only be examined using GFRα1 antibody.  GFRα1b and GFRα1 
siRNAs were shown to significantly reduce GFRα1 protein expression while 
knockdown of GFRα1a did not significantly reduce protein expression of total 
GFRα1 (Figure 3.7A, B).  This is expected as GFRα1b expression 
predominated and small changes in GFRα1a knock-down may not be easily 
visualized.  Although protein expression of Ret could not be detected by the 
antibody used (data not shown), cells transfected with Ret siRNAs 
significantly inhibited GDNF and NTN induced phosphorylation of ERK1/2 
(Figure 3.7D, E).  Interestingly, knockdown of GFRα1 and its isoforms were 
not sufficient to significantly affect GDNF and NTN induced ERK 







Figure 3.6 Knockdown effect of siRNAs on gene expression.  MCF7 cells 
were transfected with siRNAs for luciferase, GFRα1a, GFRα1b, GFRα1 or 
Ret and the expression of GFRα1a, GFRα1b and Ret mRNA were quantified 
using real-time qPCR 48 hr after transfection.  The geometric means of RPL19 
and RPL3 were used as the normalizer in this experiment.  The results were 
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Figure 3.7 Knockdown effect of siRNAs on protein expression and ERK 
phosphorylation.  MCF7 cells were transfected with siRNAs for luciferase, 
GFRα1a, GFRα1b, GFRα1 or Ret.  48 hr after transfection, the cells were 
starved overnight and stimulated with 100 ng/ml of GDNF or NTN for 10 min 
and the protein expression was examined using Western Blot.  (A) Stimulated 
cells transfected with siRNAs for luciferase, GFRα1a, GFRα1b and GFRα1 
were probed with antibody for GFRα1 and pERK.  Actin was used as a 
loading control.  (B) Fold change of GFRα1 expression were quantified using 
densitometry and shown in Mean ± SD.  ** p<0.01, compared with luciferase 
siRNA transfected cells.  (D) Cells transfected with siRNAs for luciferase and 
Ret were probed with antibody for pERK.  Actin was used as a loading control.  
(C, E) Fold change of ERK1/2 phosphoryolation were quantified using 
densitometry and normalized to untreated cells transfected with luciferase 
siRNA.  The results were presented as Mean ± SD.  ** p<0.01, compared with 






3.2.5 Knockdown of GFRα1 reduces survival of MCF7 cells  
 Significant cell death was observed after MCF7 cells were transfected 
with GFRα1 siRNAs, where the two isoforms were knocked down 
simultaneously.  To quantify the effect of siRNA knockdown on cell viability, 
the same number of MCF7 were seeded, transfected with different siRNAs 
and starved.  The observation was confirmed by the cell viability assay.  
Knockdown of GFRα1 significantly reduced viable cells.  Interestingly, 
knockdown of either one of the GFRα1 isoforms as well as the co-receptor Ret 
did not significantly affect cell viability (Figure 3.8).  Thus, it appears that the 
presence of either one of the isoforms would be sufficient for ligand 
independent survival of MCF7 cells under native conditions (untreated with 
Tamoxifen).  In addition, it is likely that other non-Ret partner was/were 
required for cell survival.      
 
 
Figure 3.8 Knockdown of GFRα1 reduced survival of MCF7 cells.  MCF7 
cells were seeded and transfected with luciferase, GFRα1a, GFRα1b, total 
GFRα1or Ret siRNAs for 24 hr and starved for 16 hr.  The viable cells were 
quantified using cell viability assay.  The survival fraction of cells was 
presented as Mean ± SEM of at least three independent experiments with six 
biological replicates.  ** p<0.01, compared to luciferase siRNA transfected 
cells.     
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3.2.6 Knockdown of Ret but not GFRα1 significantly reduced GDNF 
and NTN induced proliferation 
 In order to gain an insight into ligand induced proliferation observed 
previously (Section 3.2.2, Figure 3.2), MCF7 cells were transfected with 
siRNAs before treated with GDNF or NTN.  GDNF and NTN stimulations 
significantly increase viability in cells transfected with luciferase control, 
GFRα1a, GFRα1b and GFRα1 siRNAs.  This ligand induced proliferation was 
inhibited in Ret knockdown cells.  The fold changes of viable cells of GDNF 
and NTN stimulated Ret knockdown cells were significantly lower than the 
corresponding stimulated cells transfected with luciferase siRNA (Figure 3.9).    
 
 
Figure 3.9 Knockdown of Ret but not GFRα1 significantly affected GDNF 
and NTN induced cell proliferation.  MCF7 cells were transfected with 
luciferase, GFRα1a, GFRα1b, total GFRα1or Ret siRNAs for 48 hr before 
being trypsinized and seeded for this study.   Viable cells were quantified after 
the cells were stimulated with 100 ng/ml of GDNF or NTN for additional 96 
hr.  The fold change of viable cells was presented as Mean ± SEM of three 
independent experiments with three biological replicates.  ** p<0.01, 
compared with the corresponding stimulated cells transfected with luciferase 




3.2.7 Knockdown of Ret and GFRα1 did not significantly alterGDNF 
and NTN induced cell viability during tamoxifen treatment. 
 To examine the effect of siRNAs knockdown on survival of cells 
treated with tamoxifen, cells were transfected with different siRNAs for 48 hr 
before being exposed to different amounts of tamoxifen or ethanol vehicle for 
another 6 days.  All siRNA knockdowns did not significantly affect cell 




Figure 3.10 Knockdown of GFRα1 and Ret did not significantly affect 
survival of cells during tamoxifen treatment.  MCF7 cells were transfected 
with luciferase, GFRα1a, GFRα1b, total GFRα1or Ret siRNAs for 48 hr 
before being trypsinized and seeded for this study.   They were treated with 
ethanol vehicle or 10
-9
 M to 10
-6
 M tamoxifen with or without 100 ng/ml of 
GDNF or NTN for 6 days.  The fold change of viable cells was presented as 







 As observed previously, GDNF and NTN stimulation increase viable 
cells during tamoxifen treatment (Section 3.2.2, Figure 3.4).  Hence, siRNA 
transfected cells were used in order to find out which receptors and co-
receptors were involved.  For cells transfected with luciferase control, 
GFRα1a, GFRα1b and GFRα1 siRNAs, significantly more viable cells could 
be observed during GDNF and NTN stimulations when treated with or without 
tamoxifen.  Interestingly, although viability of GDNF and NTN stimulated Ret 
knockdown cells were found to be significantly lower than their corresponding 
stimulated cells transfected with luciferase siRNA, this phenomenon appeared 













0 M Tamoxifen 
10
-9
 M Tamoxifen 
10
-8





E    
 
Figure 3.11 Knockdown effect on GDNF and NTN induced cell survival 
during tamoxifen treatment.  MCF7 cells were transfected with luciferase, 
GFRα1a, GFRα1b, total GFRα1or Ret siRNAs for 48 hr before being 
trypsinized and seeded for this study.   They were treated with ethanol vehicle 
or 10
-9
 M to 10
-6
 M tamoxifen with or without 100 ng/ml of GDNF or NTN 
for 6 days.  The fold change was calculated after normalized to their respective 
siRNA transfected cells treated with ethanol vehicle.  The fold change of 
viable cells was presented as Mean ± SEM of three independent experiments 
with three biological replicates.  * p<0.05, compared with the corresponding 
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 In this study, NTN, like GDNF, were found to induce proliferation 
and/or survival of MCF7 human breast cancer cells.  It was rather 
unanticipated that the proliferation induced by GDNF or NTN could not be 
observed in Ret knockdown cells while knockdown of GFRα1 did not 
significantly affect GDNF or NTN induced cell proliferation and/or survival.  
Interestingly, knockdown of total GFRα1 but not either of the GFRα1 
isoforms was observed to significantly reduce basic cell survival of MCF7 
cells. 
 As previously reported [123, 125, 172], MCF7, a commonly used cell 
model, which was reported to be representative of estrogen receptor (ER) 
positive breast cancers [171], were shown to express high levels of GFRα1 
and Ret.  It is worthy to note that NTN was also intrinsically expressed in 
MCF7 cells. Although the expressions of GFRα1 and Ret have already been 
reported to be up-regulated in human breast cancer samples [125, 169], 
whether GFRα1 isoforms are expressed differentially is currently unknown.  It 
is important to note that the quantitative analysis of the expression of the 
specific isoform with existing antibodies was practically impossible with 
current technologies, as sequences of GFRα1 isoforms are highly similar.  
Hence, the expression of GFRα1 isoforms can only be detected using isoform-
specific real-time PCR.  It is interesting to find that MCF7 cells expressed 
predominantly GFRα1b.  As GFRα1b was previously reported to be 
predominantly expressed in human glioma samples and play important roles in 
glioma biology [113], it was therefore interesting to find out whether GFRα1b 
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is also predominantly expressed in ER positive breast cancer samples and play 
similar significant functions in breast cancer biology. 
In addition to GFRs, NTN was also found to be intrinsically expressed 
in MCF7 breast cancer cells.  Although NTN has been reported to be 
correlated with several cancers [109, 175, 176], its roles in breast cancer 
biology remain largely unknown.  Therefore the first part of this study 
involves uncovering the involvement of the GDNF receptor complex in breast 
cancer biology on MCF7 cell viability via the stimulation of GDNF and NTN.  
GDNF stimulation was found to induce proliferation and/or survival of MCF7 
cells in the condition with or without tamoxifen treatment.  This result is 
different with one of the reported studies [172] while consistent with the 
others [123, 125, 168].  On top of that, this study was the first to show that 
NTN stimulation also induced the proliferation and/or survival of MCF7 
breast cancer cells.  On the other hand, reports of GDNF being implicated in 
inducing the anchorage-independent proliferation and/or survival [172, 174] 
was not observed in this study.  The GDNF and NTN stimulation used in this 
study interestingly did not appear to significantly affect anchorage-
independent proliferation and/or survival in this study.  This might be 
attributed to the differences in culture condition during stimulation, such as the 
percentage of serum or occurrence of estrogen in culturing media, which may 
well contribute to such discrepancies. 
To address whether GFRα1, GFRα1a, GFRα1b and Ret play 
significant roles in GDNF related breast cancer biology, siRNAs targeting the 
respective genes were prepared and tested.  It is worthy to note that isoform-
specific siRNAs for GFRα1a and GFRα1b are not commercially available.  In 
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order to study the specific roles played by each GFRα1 isoforms, exon-
spanning siRNA duplexes that targeted the distinctive exon junction of each 
isoform were designed, according to the method described previously [113].  
One RNA duplex was selected for each GFRα1 isoform based on knockdown 
specificity and efficiency.  These isoform-specific siRNA duplexes are 
valuable tools for the study of isoform specific functions of GFRα1a and 
GFRα1b.    
 The knockdown effect of the prepared siRNA duplexes were examined 
before being used for subsequent functional studies.  All siRNAs were found 
to effectively knockdown mRNA expression of the targeted gene.  GFRα1 
protein level of cells transfected with GFRα1b or GFRα1 siRNA were 
significantly lower than cells transfected with luciferase control, indicating 
GFRα1b and GFRα1 siRNAs could successfully knockdown the protein 
expression of the targeted gene.  It is important to note that since it was not 
possible to specifically detect protein expression of the GFRα1 isoform, the 
knockdown effect of GFRα1a, which was expressed in much lower level 
comparing to GFRα1b could only be shown at the transcript level using 
isoform-specific qPCR.  Although the protein level of Ret could not be 
successfully detected, the protein analysis of ERK phosphorylation indicated 
the Ret siRNA transfection not only reduced the gene expression of Ret but 
also reduced ERK phosphorylation upon GDNF and NTN stimulation.  
Interestingly, contrary to Ret knockdown, knockdown of GFRα1, GFRα1a and 
GFRα1b did not significantly affect phosphorylation of ERK1/2 during GDNF 
and NTN stimulation.  This result suggested that the expression of GFRα1 
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might still be sufficient to induce ERK phosphorylation during GDNF and 
NTN stimulation.   
 Unexpectedly, GFRα1 knockdown significantly reduced cell survival 
of MCF7.  The viability of cells transfected with GFRα1a, GFRα1b and Ret 
siRNA did not significantly different from the cells transfected with luciferase 
siRNA.  Since MCF7 cells was shown to express NTN, this data suggested 
that autocrine activation of either GFRα1a or GFRα1b alone was sufficient to 
maintain the basic survival of MCF7 and once GFRα1 was activated, minimal 
amount of Ret was sufficient to transduce the signal into the cells.  When there 
was no additional stimulation, MCF7 might maintain basic cell survival 
without proliferation through the activation of GFRα1.  This hypothesis has to 
be further investigated before a clearer picture of how MCF7 maintain basic 
cell survival through GDNF receptor could be drawn.      
 Ret was found to play significant role in GDNF induced cell 
proliferation in MCF7 cells as reported previously [123, 125].  In this 
particular study, Ret was also shown to have significant effect on NTN 
induced cell proliferation and/or survival.  To date, the role of GFRα1 in 
GDNF induced proliferation of MCF7 cells has once been shown by knocking 
down GFRα1 and stimulating the cells with a much lower dose of GDNF (10 
ng/ml) [125].  On the contrary, the knockdown of GFRα1 and each of the 
isoforms do not significantly affect cell proliferation and/or survival induced 
by GDNF or NTN, suggesting the possibility that GFRα1 was only required in 
low amount to sustain the ligand induced proliferation and/or survival of 
MCF7.  This result was in line with the findings that, when GFRα1 was 
significantly knocked down, Erk phosphorylation induced by GDNF and NTN 
60 
 
stimulation was not inhibited while this inhibition could be seen after Ret was 
knocked down.  This result suggested that, as compared to GFRα1, where 
knockdown did not inhibit or slow down cancer proliferation, Ret appeared to 
be in the more significant component in the pathway and served as a better 
target to reduce the effect of GDNF and NTN induced proliferation and/or 
survival.  Isoform specific effects on proliferation was not observed at this 
level of simulation, which suggested that at sustained levels of simulation, 
either isoforms were enough to maintain the proliferation and/or survival of 
the cells.  In order to study whether GFRα1 isoforms play isoform specific 
roles in breast cancer biology using MCF7 cells, a lower dosage of stimulation 
might be required for isoform specific effect on proliferation to be observed.      
 The significance of GDNF complexes was further enhanced by the fact 
that approximately 70% of the diagnosed breast cancers are ER positive and 
the expression of GFRα1 was reported to be positively associated with ER 
expression [125].  While these patients could be subjected to endocrine 
therapy with drugs blocking the estrogensignaling pathway, resistance to the 
treatment developed rather rapidly.  MCF7, which was reported to be 
representative of ER positive breast cancers [171] therefore served as a good 
cell model for chemoresistance study.  In this study, the role of GDNF 
receptor complex during tamoxifen treatment was examined using MCF7 cells. 
As previously reported [168], GDNF stimulation of the MCF7 cells could 
significantly increase cell viability during tamoxifen treatment.  In this study, 
it is a first to show that NTN stimulation of MCF7 cells could also 
significantly increase viable cells during tamoxifen treatment.  However, 
knockdown of Ret in untreated MCF7 cells did not significantly reduce cell 
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survival during tamoxifen treatment, possibly due to tamoxifen already 
inhibiting MCF7 growth, masking the ret knockdown effect.  Unexpectedly, 
Ret knockdown was found to significantly inhibit NTN induced cell 
proliferation and/or survival while the GDNF stimulation could still 
significantly increase cell viability during tamoxifen treatment.  This result 
suggested that GDNF stimulation, as compared to NTN, was more potent in 
inducing cell proliferation and/or survival during tamoxifen treatment.  
Interestingly, the inhibitory effect of Ret knockdown cells on increasing cell 
viability during GDNF and NTN stimulation, as compared to their 
corresponding stimulated luciferase control, was shown to be less observable 
with increasing dosage of tamoxifen treatment.  This data was consistent with 
the recent study that showed expression of Ret could be regulated by estrogen 
stimulation [177].  Tamoxifen, an antagonist that inhibit the activation of 
estrogen receptor, could reduce the expression of Ret and hence resulted in 
similar effect of Ret knockdown.  This result suggested that inhibition of Ret, 
one of the downstream players of tamoxifen treatment and the co-receptor of 
GDNF and NTN induced cell proliferation and/or survival, could effectively 
reduce cell viability of ER positive breast cancer cells.     
 In conclusion, this study is the first to show that NTN was intrinsically 
expressed in MCF7 cells and it could induce the proliferation and/or survival 
of cells in the presence or absence of tamoxifen treatment.  It is interesting to 
find that activation of either GFRα1a or GFRα1b alone is sufficient to 
maintain the basic survival and proliferation of MCF7.  The significant effect 
of Ret knockdown on GDNF and NTN induced cell proliferation and/or 
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survival of MCF7 suggested that Ret but not GFRα1 may serve as a better 




CHAPTER 4  
CONCLUSION AND FUTURE STUDIES 
 
4.1 Conclusion 
 The GDNF receptor complex is involved in a myriad of physiological 
processes and disease progression.  Its discovery has led to multiple thorough 
studies on the signaling pathway of the complex that provided many useful 
insights in neuronal development and cancer progression.  This study further 
explored the interaction between GDNF, its previously less studied 
counterpart NTN, the receptor GFRα1 and its isoforms, and the downstream 
Ret signaling activation, in the context of neuronal differentiation and breast 
cancer progression.  In the study of GDNF receptor complex in neuronal 
differentiation and lineage specification using NT2 (an adherent neuronal 
model), it was found that GFL stimulation alone after RA stimulation did not 
affect the differentiation of NSC/NPC into neurons; they did however, altered 
the lineage specification markers when compared to RA or RA+GFL co-
stimulation. When studying the effects of culturing condition on GDNF 
receptor system expression, it was found that GDNF receptor system 
expression remained largely similar in a 2D or 3D condition, with the 
exception of NCAM expression, which may lead to differential changes in 
NSC/NPC differentiation, and should be noted in future studies of neuronal 
differentiation.  In the study of the involvement of the signaling complex in 
breast cancer, GDNF component expression profiles in MCF7 were obtained, 
and Ret has been observed to be the most significant component in the 
maintenance and chemoresistance of MCF7 cells during GDNF and NTN 
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stimulation, as compared to the other components of the signaling complex.  
These studies may then further provide the basis for further studies on GDNF 
signaling pathway models and mechanisms in their respective contexts.   
 
 
4.2 Future works 
4.2.1 Validation of the regulation of neuronal markers during 
differentiation at protein level 
 In this study, the regulation of neuronal markers was studied at the 
mRNA levels.  It is therefore interesting to examine whether similar trends of 
changes could be found at the protein levels.  This will provide a more 
complete picture of involvement of these markers in neuronal differentiation 
when exposed todifferent stimulations and culturing conditions. 
 
4.2.2 Integrative study of effects of GDNF receptor system signaling on 
DA and motor neuron differentiation in 2D and 3D cultures 
 The current study focused on elucidating the effects of GFLs' on 
neuronal differentiation, specifically where it affected and slowed down the 
differentiation of DA neurons.  The study at the same time found that culturing 
NT2 cells in 3D culture changes the expression of NCAM, which may play a 
role in the differentiation of DA and motor neurons as it belongs to the GDNF 
receptor signaling system as well.  Therefore it is interesting to combine these 
two studies and elucidate the role of GDNF receptor signaling system in DA 
and motor neuron differentiation in order to mimic as closely to physiological 
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condition as possible, which is expected to yield useful information for further 
replacement therapy studies. 
 
4.2.3 Elucidating possible GFR isoform specific neuronal differentiation 
 This study pinpointed the changes in neuronal differentiation.  It is 
now of interest to see whether the changes can be further attributed to specific 
GDNF receptor isoforms responding to the different GFL stimulants in order 
to obtain a deeper understanding in the isoform specific roles of GDNF 
receptor complex on neuronal differentiation.  The potential isoform 
difference may provide deeper insights in stem cell based medicine.  
 
4.2.4 Profiling of GFRα1 isoforms in clinical breast cancer samples 
 The profiling of GFRα1 isoforms in breast cancer can also be extended 
to clinical samples.  The difference in the expression levels of GFRα1 
isoforms in MCF7 cells suggested that there are other functions carried out 
specifically by each isoforms, which may lead to slightly different phenotype 
in different samples.  It is therefore interesting to further profile the expression 
of different isoforms in clinical samples in order to assess the effect of 
expression difference on the phenotype of the tumor.  Differences in 
expression in clinical samples may also be further characterized and 
catalogued where these GFRα1 isoforms may serve as biomarkers of breast 






4.2.5 Further study of isoform specific roles in breast cancer 
 The study can be further extended to elucidate the possible roles of 
GFRα1 isoform in breast cancer biology with lower levels of GDNF 
stimulation.  Isoform specific roles were speculated to be more prominent at 
lower levels of growth factor stimulation as the isoform specific variation was 
insignificant with the level of stimulation in the current study.  However, the 
possibility of isoform specific roles could not be ruled out, in particular when 
cancer cells were starved of nutrients.  Therefore the lower levels of GDNF 
stimulation can mimic the starvation of cancer cells and possibly will allow 
any isoform specific function to be observed. 
 
4.2.6 GFRα1 in cancer migration and invasiveness  
 Recent study has elucidated the relationship between IL-6 and Ret in 
increasing the migration and invasiveness of breast cancer cells [174].  It is 
therefore also interesting to further study the roles of GFRα1 in the migration 
of the cancer cell as they are known to be closely involved in Ret mediated 
physiological function.  The study can also be further expanded down into 
looking at whether there are any isoform specific mediation of cancer cell 
migration and invasiveness with GFRα1, which may be useful in curbing 




CHAPTER 5  
MATERIAL AND METHODS 
 
5.1 Ligands and chemicals 
 Human recombinant GDNF and NTN were purchased from Peprotech 
(Rocky Hill, NJ, USA).  All-trans retinoic acid (RA) and Tamoxifen were 
purchased from Sigma Aldrich (Saint Louis, MO, USA).  Primary antibody 
against phospho-specific Erk1/2 (Thr202/Tyr204) (pErk) was purchased from 
Cell Signaling Technologies (Danvers, MA, USA).  Antibodies for GFRα1 
and Ret were from R&D Systems (Minneapolis, MN, USA).  Primary 
antibody against actin was from Sigma Aldrich (Saint Louis, MO, USA).  
Secondary antibodies conjugated with horseradish peroxidase (HRP) were 
purchased from Thermo Scientific (Wilmington, DE, USA).   
 
5.2 Cell culture 
5.2.1 Mammalian cell lines and culture conditions 
 Human embryonal carcinoma Ntera-2 cl.D1 cells (NT2; ATCC catalog 
# CRL-1973; ATCC, Manassas, VA, USA) and human breast cancer cell lines, 
MCF7 (ATCC catalog # HTB-22) were cultured in complete medium 
comprising Dulbecco‟s modified Eagle‟s medium (DMEM; Sigma Aldrich, 
Saint Louis, MO, USA) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS; HyClone, Logan, UT, USA), 100 units/ml penicillin (Pan 
Biotech, Aidenbach, Germany) and 100 μg/ml streptomycin (Pan Biotech, 
Aidenbach, Germany).  The cells were maintained at 37 ˚C in a humidified 
atmosphere with 5% carbon dioxide (CO2).  
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5.2.2 Neuronal Differentiation 
 To carry out neuronal differentiation, NT2 cells were seeded in 6-well 
plates (Nalge NUNC International, Penfield, NY, USA) in complete media 
overnight before treated with 10 μM RA.  The media was replaced every 72 hr 
for a period of 24 days.   
 In order to test the effect of different ligands on neuronal 
differentiation, RA differentiation protocol was modified by replacing RA 
with different neuronal differentiation ligands.  NT2 cells were first seeded in 
T75 flasks (Nalge NUNC International, Penfield, NY, USA) in complete 
media overnight before treated with 10 μM RA for the first 7 days.  Then, the 
cells were trypsinized and seeded on 6-well plates (Nalge NUNC International, 
Penfield, NY, USA).  The cells were treated directly with 10 μM RA or 
treated with various combination of other ligands -100 ng/ml GDNF alone; 
100ng/ml NTN alone; 10 μM RA with 100 ng/ml GDNF; and 10 μM RA with 
100 ng/ml NTN.  The media was replaced every 72 hr for another 12 days.   
 
 
5.2.3 Cells cultured on or in collagen gel      
 Cells were cultured on collagen gel (2D substrate), by mixing 
appropriate amount of the acid-solubilized rat tail type-I collagen (BD 
Biosciences, Bedford, MA, USA) with 10x PBS on ice.  One molar of sodium 
hydroxide (NaOH) was used to adjust the pH of the solution to 7.4.  Complete 
media was then added to obtain the desired volume of 600 μl with 3 mg/ml 
collagen and 1x PBS.  The collagen solution was pipetted into 24-well plates 
(Nalge NUNC International, Penfield, NY, USA) and incubated at 37 ˚C for 1 
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hr to allow gelation.  NT2 cells (1.6 x 10
5
) were seeded on the collagen gel 
overnight before stimulated with 10 μM RA.  The media was replaced every 
72 hr.  The cells were collected for further study after 7 days of stimulation.  
 For cells cultured in collagen gel (3D substrate), appropriate amount of 
the acid-solubilized rat tail type-I collagen (BD Biosciences, Bedford, MA, 
USA) were mixed on ice with 10 x PBS.  One molar sodium hydroxide 
(NaOH) was used to adjust the pH of the solution to 7.4.  NT2 cells (3 x 10
5
) 
in complete media were added to the mixture to obtain the desired total 
volume of 600 μl with 3 mg/ml collagen and 1x PBS.  The collagen-cell 
mixture was pipetted into 24-well plates (Nalge NUNC International, Penfield, 
NY, USA) and incubated at 37 ˚C for 1 hr to allow gelation.  Fresh complete 
media was added on top of the gel subsequently.  The cells were stimulated 
with 10 μM RA the next day and the media was replaced every 72 hr.  The 
cells were collected for further study after 7 days of stimulation.    
 As a control of this study, NT2 cells (3 x 10
4
) were seeded directly on 
6-well plate (Nalge NUNC International, Penfield, NY, USA) overnight 
before treated with 10 μM RA.  The media was replaced every 72 hr for 7 
days.   
 
5.2.4 Transfection of small interfering RNA 
 Small interfering RNA (siRNA) duplexes specific for GFRα1a and 
GFRα1b were designed against the unique exon junctions.  Luciferase control 
siRNA and siRNAs for GFRα1a and GFRα1b were purchased from Sigma 
Aldrich (Saint Louis, MO, USA).  SiRNAs for GFRα1 (sc-35469) and Ret (sc-
36404) were from Santa Cruz Biotechnologies (Santa Cruz, CA, USA).  
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Transient transfection of siRNA was carried out using Transfectin (Bio-Rad, 
Hercules, CA, USA) according to manufacturer‟s protocol.  Briefly, MCF7 
cells were seeded to 80% confluency in complete media without antibiotics for 
24 hr.  Transfectin and the siRNA duplexes were diluted separately in serum-
free DMEM for 5 min.  The two solutions were then combined and incubated 
for 20 min at room temperature to enable complex formation.  MCF7 cells 
were then added drop-wise with the transfection mixture.  The transfection 
mixture containing media were replaced by fresh media 16 hr after 
transfection.  GFRα1a and GFRα1b siRNAs were used at a final concentration 
of 20nM while 10 nM of Ret and GFRα1 siRNAs were used in the 
transfection in order to achieve a similar knockdown efficiency of the 
respective targeted genes.  As a control, 20 nM of luciferase siRNA was used 
to transfect the cells.  Cells were trypsinized and seeded for functional studies 
48 hr after transfection.  Target sequences for all the siRNA duplexes are 





Table 5.1 Target sequences of siRNA duplexes.  
Target gene siRNA target sequence (5’ to 3’) 
Luciferase control CGTACGCGGAATACTTCGA 
GFRα1a #1 CATATCAGATGTTTTTCAGC 
GFRα1a #2 TATCAGATGTTTTTCAGCAA 
GFRα1b #1 GTCCCATTCATATCAGTGGA 
GFRα1b #2 CCCATTCATATCAGTGGAGC 
GFRα1b #3 ATTCATATCAGTGGAGCACA 
 
 
 To test the transfection efficiency at the transcription level, the cells 
were lysed in TRIzol reagent (Invitrogen, Carlsbad CA, USA) 48 hr after 
transfection.  RNA was extracted and RT-qPCR was carried out to confirm the 
knockdown of expression of siRNA targets post transfection.  In order to 
assess the transfection efficiency at the protein level, the 48 hr post 
transfection cells were starved overnight in DMEM supplemented with 0.5% 
FBS and lysed in 2% sodium dodecyl sulphate (SDS; Vivantis Technologies, 
Subang Jaya, Malaysia) after 10 min of 100 ng/ml GDNF or NTN stimulation.  
To test the effect of knockdown on cell viability, the media was replaced with 
DMEM supplemented with 0.5% FBS at 24 hr post transfection for another 16 
hr before cell viability assay was carried out.   
  
5.3 Analysis of breast cancer cell phenotype 
5.3.1 Cell proliferation 
 MCF7 cells (7 x 10
3
) were seeded on 96-well plates overnight before 
stimulated with 100 ng/ml of GDNF or NTN in DMEM supplemented with 
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0.5% FBS for an additional 96 hr.  The media was changed every 48hr.  
Viable cells were quantified using cell viability assay.   
 
5.3.2 Anchorage-independent proliferation 
 The anionic polymer polyHema (12 mg/ml in 95% ethanol; Sigma 
Aldrich, Saint Louis, MO, USA) was used to coat the 96-well plates according 
to the protocol to prevent cell adhesion [178].  MCF7 cells (1 x 10
4
) were 
seeded on polyHema-coated plates and immediately treated with 100 ng/ml of 
GDNF or NTN of an additional 96 hr.  Viable cells were quantified using cell 
viability assay.   
 
5.3.3 Tamoxifen response assays 
 MCF7 cells (7 x 10
3
) were seeded in 96-well plates overnight.  The 





 M tamoxifen with or without 100 ng/ml of GDNF or 
NTN.  The drug mixtures were replaced every 48 hr.  Viable cells were 
quantified using cell viability assay after 6 days of drug treatment.   
 
5.3.4 Cell viability assay 
 Twenty microliter of Cell Titer 96 Aqueous One Solution Cell 
Proliferation Assay (Promega, Fitchburg, WI, USA) was added into each well 
of the 96-well plates (Nalge NUNC International, Penfield, NY, USA) 
containing the samples  with 100 μl of DMEM.  After 1 hr incubation at 37 ˚C 
in a humidified atmosphere of 5% CO2, the absorbance at 490 nm was 
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recorded using a 96-well Microplate reader (Sunrise, Tecan, Mannedorf, 
Switzerland).    
 
5.4 Analysis of gene expression 
5.4.1 Total RNA extraction    
 Total RNA from NT2 cells was purified using RNeasy Mini Kit 
(Qiagen, Hilden, Germany) according to manufacturer‟s protocol.  Total RNA 
from MCF7 cells was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) 
according to manufacturer‟s instruction.  RNA concentration was quantified 
using NanoDrop 2000 spectrophotometer (Thermo Scientific, Wilmington, DE, 
USA) and the 260/280 and 260/230 ratios were examined to ensure RNA 
samples were free of protein and solvent contamination.   
 
5.4.2 Reverse transcription 
 Total RNA samples were reverse transcribed using ImPromII reverse 
transcriptase (Promega, Fitchburg, WI, USA), 0.5 μg random hexamer, 1x 
ImPromII Reaction Buffer (Promega, Fitchburg, WI, USA), 2.5 mM MgCl2 
and 1mMdNTP in a total volume of 20 μl for 60 min at 42 ˚C.  The solution 
was then heated at 72 ˚C for 10 min to terminate the reaction.   
 
5.4.3 Real-time quantitative PCR 
 Real-time qPCR was used to quantify the gene expression levels using 
gene specific primers listed in Table 5.2.  It was performed on the CFX96 
(Bio-Rad, Hercules, CA, USA) in a total volume of 25 μl or on the CFX384 
(Bio-Rad, Hercules, CA, USA) in a total volume of 10 μl using SYBR Green I.  
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The reaction was performed in 1 x XtensaMix-SG (BioWORKS, Singapore) 
containing 2.5mM MgCl2, 200 pmol of each primer and 0.5 U KlearTaq DNA 
polymerase (LGC Genomics, Teddington, UK).   The CFX manager software 
(Bio-Rad, Hercules, CA, USA) was used to automatically calculate the 
threshold cycles (Ct). 
 Absolute real-time PCR quantifications of GDNF receptor complexes 
of MCF7 were carried out simultaneously with linearized plasmid standards.  
The gene expression levels were interpolated from standard curves and 
normalized to the expression of GAPDH in the same samples.  RPL19 and 
RPL3, instead of GAPDH were used as reference gene for other gene 
expression studies.  The Ct values of the tested genes were first transformed 
into relative quantities before they were divided by the normalization factors 
which were calculated from the geometric means of the relative quantities of 
RPL19 and RPL3.  The fold changes were calculated using the normalized 
relative quantities of two groups of samples.   
 
5.5 Western blot analysis 
 Before western blot analysis was carried out, the protein concentrations 
of the total cell lysates were quantified using the microBCA assay (Pierce, 
Rockford, IL, USA).  The protein samples were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto 
nitrocellulose membranes, blocked with 5% (w/v) skim milk in TBS-T 0.1% 
at 37 ˚C for 1 hr, followed by overnight incubation at 4 ˚C with primary 
antibodies against pERK (1:2000 dilution), GFRα1 (1:500 dilution), Ret 
(1:250 dilution) and actin (1:10,000 dilution).  After which, the membranes were 
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incubated with secondary HRP-conjugated antibodies at 37 ˚C for 1 hr.  The 
protein bands were visualized by Immobilon Western Chemiluminescent HRP 
Substrate (Millipore, Billerica, MA, USA) on a ChemiDoc XRS system (Bio-
Rad, Hercules, CA).  The band intensities were quantified using Image Lab 




Table 5.2 Details of primers for real-time qPCR  
Gene Forward primer (5' to 3') Reverse primer (5' to 3') 
A. GDNF receptor complexes 
GDNF  ATGAAACCAAGGAGGAACTGATTT CTGCCCTACTTTGTCACTCAC 
NTN GGTTCCCTGTGACTCCTG CTTTGACTTTGAACGCCTG 
GFRα1 GCCTGTGTGCTCCTATGAAG CTGGCTGGCAGTTGGTAAA 
GFRα1a CATATCAGATGTTTTTCAGCAAGTGGA CAGACATCGTTGGACACGCT 
GFRα1b TGGTCCCATTCATATCAGTGGA CAGACATCGTTGGACACGCT 
GFRα2 CAGTGACAGTACCAGCTTGGG AAGGCCTGTTTCAGCATCAG 
RET AGCGGCTCTTCAACCTTCTG CTCCTCTTAACCATCATCTTCTCC 
NCAM CAGCAGCGGATCTCAGTGGT CATCACACACAATCACGGCA 
   
B. Neuronal markers and markers for neuronal lineages 
NEFH CCGTCATCAGGCCGACATT GTTTTCTGTAAGCGGCTATCTCT 
Tubb3 GGGCCTTTGGACATCTCT CACATCCAGGACCGAATC 
VGLUT CGACGACAGCCTTTTGTGGT GCCGTAGACGTAGAAAACAGAG 
GLS-1 GGTCTCCTCCTCTGGATAAGATGG CCCGTTGTCAGAATCTCCTTGAGG 
GLS-2 GGTCTCCTCCTCTGGATAAGATGG GATGTCCTCATTTGACTCAGGTGAC 
ChAT GGAGCCTGAGCACGTCATC CAACTGAGTGAACAGATCCCC 
VAChT TTCGCCTCTACAGTCCTGTTC GCTCCTCCGGGTACTTATCG 
ACHE AGAGCTGGTAGCCTGCCTT CCGGAAGACGCTTTCTTGAGG 
Mash1  TCTCGACTTCACCAACTG CACTGACAAGAAAGCACTAAA 
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Islet1 AAGGACAAGAAGCGAAGCAT TTCCTGTCATCCCCTGGATA 
Nurr1 CCTGTAACTCGGCTGAAG GTGGTAACTGTAGCTCTGA 
DAT CCCATACTGAAAGGTGTG GTGAAGGAGGAGAAGAGAT 
Msx1 AGACGCAGGTGAAGATATGG ATCTTCAGCTTCTCCAGCTC 
EN1 GCCAAGATCAAGAAAGCCAC TACTCGCTCTCGTCTTTGTC 
GIRK2 CATGATTGAGTGAAGCCACC AGGACGTTAGTCATGGATTCTG 
Otx2 GTACCCAGACATCTTCATGC GATTCTTAAACCATACCTGCACC 
TH GCCCTACCAAGACCAGACGTA CGTGAGGCATAGCTCCTGA 
C. Reference genes 
GAPDH ACCCACTCCTCCACCTTTGAC TCCACCACCCTGTTGCTGTAG 
RPL19 TCAGGCTTCAGAAGAGGCT GGAGTTGGCATTGGCGATT 
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